# Inflation Reduction Act

Type: Company

Source: GetYourBrief — https://getyourbrief.com/entity/inflation-reduction-act-company
Canonical HTML page: https://getyourbrief.com/entity/inflation-reduction-act-company

## Timeline

- **2026-08-04**: En Banc D.C. Circuit Reverses Panel and Restores Injunction — A 10-judge en banc panel rules that the EPA cannot block the grants, reinstating the district court's April 2025 injunction; distribution stayed pending possible Supreme Court appeal.
- **2025-09**: D.C. Circuit Panel Overturns Injunction — A three-judge panel of the D.C. Circuit votes 2-1 to reverse the injunction, holding that the nonprofits should have sued in the U.S. Court of Federal Claims.
- **2025-04**: District Court Issues Injunction — A federal district court orders the EPA to disburse the funds, finding that the agency's freeze likely violates grant agreements.
- **2025-03**: EPA Freezes Climate Grants — EPA Administrator Lee Zeldin suspends disbursement of approximately $20 billion in grants awarded to eight nonprofit entities, citing policy alignment and fraud concerns.
- **2022-08**: Inflation Reduction Act Signed — Congress passes the Inflation Reduction Act, establishing the $27 billion Greenhouse Gas Reduction Fund for clean energy grants and financing.

## Recent coverage (2 stories, network-wide)

### En Banc Ruling: EPA Cannot Claw Back $20B in Climate Grants, Supreme Court Next
2026-08-05 00:21:25 · Sector: legal · Sentiment: Positive · Impact: 8/10 · Sources: 3

The D.C. Circuit's en banc decision reinstated an injunction barring the EPA from terminating $20 billion in IRA-awarded clean energy grants. The ruling raises separation-of-powers questions and sets the stage for a Supreme Court showdown over the limits of executive discretion on congressionally appropriated funds.
Full story: https://getlegalbrief.com/story/epa-20b-grant-clawback-en-banc-ruling

### Medicare Part D Subsidy Ends: How Pharma & Biotech Face a $3.6B Shift in Patient Costs
2026-07-30 21:24:46 · Sector: bio · Sentiment: Negative · Impact: 7/10 · Sources: 5

Termination of the temporary Medicare Part D subsidy by the Trump administration could shift $3.6 billion in costs, affecting drug pricing dynamics and patient adherence, with implications for pharma and biotech companies reliant on senior populations.
Full story: https://getbiobrief.com/story/medicare-part-d-subsidy-pharma-biotech-impact

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.